jadpro live 2023 - standardizing extended endocrine therapy decision-making
Published 9 months ago • 115 plays • Length 42:09Download video MP4
Download video MP3
Similar videos
-
5:04
standardizing extended endocrine therapy recommendations
-
41:53
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
1:39
utilizing the appropriate tool for extended endocrine therapy decision-making: bci vs oncotype dx
-
6:35
extended endocrine therapy: who will benefit?
-
53:42
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
16:19
breast cancer index, extended endocrine therapy | elizabeth ott, pa | 2022 west oncology app updates
-
2:26
consideration of side effects in extended endocrine therapy decision making
-
1:50
challenges with patient selection for extended adjuvant endocrine therapy in breast cancer
-
0:41
what genomic assay is best suited for the extended endocrine therapy decision?
-
1:42
key takeaways from the jadpro live 2023 session on metastatic breast cancer
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
0:35
how does breast cancer index help with patient selection for extended endocrine therapy?
-
26:34
cdk 4/6 inhibitors in breast cancer advanced and adjuvant settings
-
10:02
breast cancer: extended adjuvant endocrine therapy
-
0:45
do clinical and pathological factors preduct extended endocrine benefit
-
30:22
adjuvant therapy | 2023 ku breast cancer year in review conference